Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif, Fudan University, China

Dr. Mohammed Ahmed Akkaif is a Postdoctoral Researcher in the Department of Cardiology at Fudan University, China. He earned his Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia in 2023, specializing in precision medicine, pharmacogenetics, and cardiology. A Young Ambassador for the European Association of Preventive Cardiology (2022–2024), he has published 34 peer-reviewed articles, with 29 indexed in SCI, and has over 2,179 citations. Recognized with the Young Researchers Award (ESC Asia 2022), he is a reviewer for 50+ high-impact journals. His research focuses on optimizing antithrombotic drug therapies through pharmacometabolomics for personalized cardiovascular treatment.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Mohammed Ahmed Akkaif began his academic journey with a strong foundation in Clinical Pharmacy at Universiti Sains Malaysia, where he completed his Doctor of Philosophy (PhD) in July 2023. During his PhD, he focused on the intersection of clinical pharmacy and biotechnology, gaining expertise in personalized and precision medicine. His academic accomplishments included publishing 10 articles (8 in SCI Q1 and Q2 journals) and presenting at six international conferences. This period also saw him design innovative approaches to enhance antithrombotic drug treatment, particularly through CYP2C19 genotype-guided antiplatelet therapy.

💼PROFESSIONAL ENDEAVORS:

Currently, Dr. Akkaif serves as a Postdoctoral Researcher in the Department of Cardiology at Fudan University’s Qingpu Branch of Zhongshan Hospital, China. His role involves leading advanced research in cardiovascular medicine, with a specialized focus on the clinical application of personalized medicine in cardiology. Additionally, he has served as a Young Ambassador for the European Association of Preventive Cardiology (EAPC) from 2022 to 2024, demonstrating his commitment to advancing heart health on a global scale. He has also contributed his expertise to several prestigious journals, with over 50 reviews in high-impact journals such as Journal of the American Heart Association and Arteriosclerosis, Thrombosis, and Vascular Biology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR PHARMACOLOGY:

Dr. Akkaif’s research is primarily focused on pharmacogenetics and pharmacometabolomics, with a goal of improving personalized treatment strategies in cardiology. His work delves into the optimization of antithrombotic drug therapies through genetic and metabolic profiling, which holds the potential to revolutionize treatment protocols, making them more tailored to individual patient profiles. His research also bridges the gap between clinical pharmacy and biotechnology, aiming to develop more effective, individualized approaches to cardiovascular health.

🌍IMPACT AND INFLUENCE:

Dr. Akkaif’s contributions have already made a significant impact on both academic research and the practical application of precision medicine. He has been honored with the Young Researchers Award at the 2022 ESC Asia Conference in Singapore, highlighting his early recognition in the field. His research has also led to the publication of 34 peer-reviewed articles, with 29 of them indexed in SCI (Clarivate), reflecting his growing influence in the field of cardiovascular pharmacology. His work has contributed to advancing the understanding of genetic factors in drug response, and his findings are regularly cited by researchers and clinicians alike.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Akkaif’s publications have earned him considerable academic recognition, with a cumulative citation count of 2,179 as of now. This citation count reflects the profound influence his work has had on the scientific community, particularly in the areas of pharmacogenetics, pharmacometabolomics, and cardiology. His ability to produce impactful, high-quality research is evident through his consistent presence in top-tier journals, where his findings continue to shape the discourse on personalized medicine.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

As Dr. Akkaif continues his postdoctoral work at Fudan University, his future contributions are poised to expand on his research in precision medicine and cardiology. Given his accomplishments thus far, his research promises to lead to more personalized treatment options for cardiovascular diseases, potentially transforming clinical practices and improving patient outcomes globally. His ongoing efforts in understanding the genetic and metabolic factors influencing drug efficacy will likely place him at the forefront of the personalized medicine movement, paving the way for future innovations in the medical field.

🏆KEY AWARDS AND HONORS:

  • Young Researchers Award at the 2022 ESC Asia Conference (Singapore)

  • Second Prize for the Young Investigator Award at the ESC Asia Congress in Singapore 2022

  • Young Ambassador of the European Association of Preventive Cardiology (EAPC) (2022–2024)

  • Reviewing Excellence for over 50 high-impact SCI Q1 and Q2 journals

🌍CONCLUSION:

Dr. Mohammed Ahmed Akkaif’s groundbreaking research in precision medicine and cardiology continues to shape the future of personalized healthcare. With a strong academic background, numerous publications, and recognition through prestigious awards, his work is making significant contributions to improving cardiovascular treatments. His role as a Young Ambassador for the European Association of Preventive Cardiology further highlights his dedication to global health. As he advances his postdoctoral research at Fudan University, Dr. Akkaif’s future endeavors hold the potential to revolutionize clinical practices, particularly in pharmacogenetics and pharmacometabolomics, ensuring more effective and individualized patient care.

TOP NOTABLE PUBLICATIONS:

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …

Authors: AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, …

Journal: The Lancet

Year: 2024

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …

Authors: M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, …

Journal: The Lancet

Year: 2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the …

Authors: The Lancet

Year: 2024

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Authors: M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, …

Journal: The Lancet

Year: 2024

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Authors: SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Authors: VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, …

Journal: The Lancet Neurology

Year: 2024

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Authors: NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Authors: MA Akkaif, NAA Daud, A Sha’aban, ML Ng, MAS Abdul Kader, DA Noor

Journal: Molecules

Year: 2021

A review of the effects of ticagrelor on adenosine concentration and its clinical significance

Authors: MA Akkaif, ML Ng, MASA Kader, NAA Daud, A Sha’aban, B Ibrahim

Journal: Pharmacological Reports

Year: 2021

National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

Authors: M Ng, X Dai, RM Cogen, M Abdelmasseh, A Abdollahi, A Abdullahi, …

Journal: The Lancet

Year: 2024

 

Dandan Tian | Hypertension | Best Researcher Award

Dr. Dandan Tian | Hypertension | Best Researcher Award

Dr.  Dandan Tian, Henan Provincial People’s Hospital, China

Dr. Dandan Tian is a medical professional at Henan Provincial People’s Hospital in China. With a focus on clinical practice, her expertise spans a variety of medical specialties, particularly in patient care and hospital management. Dr. Tian has made significant contributions to advancing healthcare in the region through her dedication to improving medical services and patient outcomes. She is well-regarded for her professional approach, collaboration with medical teams, and commitment to providing high-quality healthcare. Dr. Tian’s work has also involved research and development aimed at enhancing medical practices and addressing regional healthcare challenges.

Author Profile

Scopus Profile

EARLY ACADEMIC PURSUITS:

Dr. Dandan Tian’s academic journey laid a solid foundation for her distinguished career in hypertension prevention and treatment. After completing her formal medical education, she focused her studies on cardiovascular diseases, particularly hypertension, which has remained a central theme throughout her career. Her commitment to medical research, along with her clinical training, enabled her to understand the complexities of hypertension, and she quickly became passionate about improving treatment protocols and preventative care measures. Early on, her academic curiosity and dedication positioned her to contribute significantly to the growing body of knowledge in her field.

PROFESSIONAL ENDEAVORS:

Dr. Tian currently serves as the Attending Physician in the Hypertension Department of Henan Provincial People’s Hospital. This prestigious role allows her to apply her expertise in diagnosing and treating hypertension while maintaining a hands-on approach with patient care. Beyond her clinical responsibilities, Dr. Tian has taken on significant leadership roles, including Secretary of the Hypertension Prevention and Treatment Center of Henan Province and Secretary of the Hypertension Targeted Center Alliance. Her professional endeavors emphasize collaboration and innovation, as she continues to be a key player in hypertension care across the region.

CONTRIBUTIONS AND RESEARCH FOCUS ON HYPERTENSION:

Dr. Tian’s research focus has been on advancing hypertension prevention, treatment, and management through evidence-based practices. She has made substantial contributions to the field by leading one provincial-level research project and participating in multiple national-level research efforts. These research projects aim to enhance the clinical understanding of hypertension, explore new treatment methods, and implement effective prevention strategies. Her involvement in ministerial and provincial-level research further highlights her commitment to improving public health and addressing hypertension on a broader scale.

IMPACT AND INFLUENCE:

Dr. Tian’s impact extends beyond her clinical and research work. Her leadership in the Hypertension Prevention and Treatment Center of Henan Province and her membership in key medical societies, including the Henan Microcirculation Society, have solidified her influence in the medical community. Additionally, she plays a vital role in shaping healthcare policy and practice, particularly regarding hypertension management and prevention. Dr. Tian was recognized as an exemplary individual in disease prevention and control work by the province in 2021, reflecting the widespread acknowledgment of her contributions to public health.

ACADEMIC CITES AND RECOGNITION:

Dr. Tian’s research has garnered significant academic recognition, with citations from peers and professionals in the field of hypertension and cardiovascular health. Her work on hypertension prevention and treatment protocols has been widely cited, contributing to the academic discourse on hypertension management both within China and internationally. This recognition serves as a testament to the relevance and impact of her research in improving hypertension care practices.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Tian’s legacy is shaped by her pioneering work in hypertension prevention and her dedication to improving patient outcomes. Her research and clinical expertise continue to inspire future generations of healthcare professionals and researchers. Moving forward, Dr. Tian’s contributions are expected to pave the way for further advancements in hypertension management, particularly with her ongoing leadership in various professional committees and research projects. She is committed to continuing her work in hypertension treatment and prevention, and her future contributions are likely to have an enduring impact on the field.

CONCLUSION:

Dr. Dandan Tian’s career reflects a deep commitment to both the clinical and academic sides of hypertension management. Her early academic pursuits, professional endeavors, and continued contributions to research have established her as a leader in the field. Through her work, she has influenced both healthcare policy and patient care practices. With a lasting impact on hypertension prevention, Dr. Tian is poised to continue making significant contributions to the field, solidifying her place as a leading figure in cardiovascular health.

TOP NOTABLE PUBLICATIONS

Article: Effects of obesity on aging brain and cognitive decline: A cohort study from the UK Biobank

Authors: Li, P., Zhu, X., Huang, C., Su, J., Tian, D.

Journal: IBRO Neuroscience Reports

Year: 2025

Article: Joint Exposure to Ambient Air Pollutants, Genetic Risk, and Ischemic Stroke: A Prospective Analysis in UK Biobank

Authors: Li, P., Wang, Y., Tian, D., Su, J., Wang, M.

Journal: Stroke

Year: 2024

Article: Analysis of clinical and biochemical characteristics and left ventricular hypertrophy in patients with indeterminate saline infusion test results

Authors: Qu, H., Zhao, J., Wang, L., Hao, Y., Liu, M.

Journal: Frontiers in Endocrinology

Year: 2024

Article: Causal factors of cardiovascular disease in end-stage renal disease with maintenance hemodialysis: a longitudinal and Mendelian randomization study

Authors: Tian, D., Xu, Y., Wang, Y., Li, P., Li, X.

Journal: Frontiers in Cardiovascular Medicine

Year: 2024

Article: Association Between Plasma Levels of ANGPTL3, 4, 8 and the Most Common Additional Cardiovascular Risk Factors in Patients with Hypertension

Authors: Xu, F., Shen, L., Yang, Y., Cao, X., Huang, G.

Journal: Diabetes, Metabolic Syndrome and Obesity

Year: 2023

Article: Analysis of the Expression and Prognostic Potential of a Novel Metabolic Regulator ANGPTL8/Betatrophin in Human Cancers

Authors: Xu, F., Tian, D., Shi, X., Sun, K., Chen, Y.

Journal: Pathology and Oncology Research

Year: 2021

Article: Highly sensitive and selective photoelectrochemical sensor for mercury(II) detection based on efficient Bi2MoO6 photoanode decorated with CuS

Authors: Zhang, X., Li, M., He, L., Zhang, J., Liu, M.

Journal: Journal of Alloys and Compounds

Year: 2021

Article: ANGPTL8/betatrophin improves glucose tolerance in older mice and metabolomic analysis reveals its role in insulin resistance in HepG2 cells

Authors: Xu, F., Wang, N., Li, G., Tian, D., Shi, X.

Journal: Diabetes, Metabolic Syndrome and Obesity

Year: 2021

Article: Modeling analysis of the relationship between atherosclerosis and related inflammatory factors

Authors: Li, H., Zhang, P., Yuan, S., Tian, D., Liu, M.

Journal: Saudi Journal of Biological Sciences

Year: 2017